Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06839235 · ClinicalTrials.gov registry record · Phase 1
Phase 1/2 Study of ABO-101 in Primary Hyperoxaluria Type 1 (redePHine)
A Phase 1 study of Primary Hyperoxaluria Type 1 (PH1), sponsored by Arbor Biotechnologies.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 23
- Enrollment target
- 7
- Study locations
NCT06839235: Recruiting Phase 1 study of Primary Hyperoxaluria Type 1 (PH1), sponsored by Arbor Biotechnologies.
NCT06839235 is a Phase 1 study of Primary Hyperoxaluria Type 1 (PH1) that is actively recruiting participants, run by Arbor Biotechnologies. The registered enrollment target is 23 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (62% lower). The trial reports 7 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06839235, a Phase 1 study of Primary Hyperoxaluria Type 1 (PH1), is actively recruiting participants, sponsored by Arbor Biotechnologies.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 23 participants
- Enrollment target
- 7
- Study locations
Study Summary
The goal of the redePHine study is to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of ABO-101 in participants with primary hyperoxaluria type 1 (PH1). The trial will consist of 2 Study Periods. During the first Study Period, there will be 2 parts. In Part A, adult participants will be treated with a single ascending dose to identify a recommended dose. In Part B, pediatric participants will be treated with the recommended dose. Following the first Study Period, participants will start Study Period 2, a long-term monitoring program to comply with local and national requirements.
Conditions Studied
Interventions
- DRUG ABO-101
Study Locations (7)
Other
- Hospices Civils de Lyon- Hôpital Femmes Mères Enfants - Lyon
- Kindernierenzentrum Bonn - Bonn
- Heidi Chaker - Sfax
- Queen Elizabeth Hospital Birmingham - Birmingham
- Royal Free Hospital - London
Minnesota
- Mayo Clinic - Rochester
- Nucleus Network - Saint Paul
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 23 participants |
| Start Date | 2025-06-16 |
| Est. Completion | 2043-02 |
| Phase | Phase 1 |
What NCT06839235 shows while recruiting
NCT06839235 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 23 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (62% lower).
The record links to 1 condition, with Primary Hyperoxaluria Type 1 (PH1) appearing as the primary indexed condition, and to 1 intervention - of which ABO-101 is the first listed.
NCT06839235 lists 7 locations in 2 states (Other, Minnesota).
Frequently Asked Questions
What is clinical trial NCT06839235 about?
NCT06839235 is a clinical study titled "Phase 1/2 Study of ABO-101 in Primary Hyperoxaluria Type 1 (redePHine)". The goal of the redePHine study is to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of ABO-101 in participants with primary hyperoxaluria type 1 (PH1). The trial will consist of 2 Study Periods. During the first Study Period, there will be 2 parts. In Part A, adult partic...
What is the current status of trial NCT06839235?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 23 participants. The study started on 2025-06-16. Estimated completion is 2043-02.
What conditions does trial NCT06839235 study?
This clinical trial studies the following conditions: Primary Hyperoxaluria Type 1 (PH1).
What interventions are being tested in trial NCT06839235?
The interventions under investigation include: ABO-101 (DRUG).
Who is sponsoring clinical trial NCT06839235?
This trial is sponsored by Arbor Biotechnologies, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06839235 being conducted?
This trial has 7 study locations across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Primary Hyperoxaluria Type 1 (PH1)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06839235's enrollment target sits among peer trials
23 1597th of 2000 higher than 400 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03616041 · 23 participants
Capsule Endoscopy for Severe Hematochezia
- NCT04348747 · 23 participants · Phase 2
Dendritic Cell Vaccines Against Her2/Her3 and Pembrolizumab for the Treatment of Brain Metastasis From Triple Negative Breast Cancer or HER2+ Breast Cancer
- NCT04587687 · 23 participants · Phase 2
Brentuximab Vedotin and Bendamustine for the Treatment of Relapsed or Refractory Follicular Lymphoma
- NCT04715022 · 23 participants · Phase 1
Sympathetic-vascular Dysfunction in Obesity and Insulin Resistance (Vitamin C Study)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI